• NewAmsterdam Pharma announced that it will present data at the 2026 Alzheimer’s Association International Conference in London on obicetrapib, an oral, low-dose CETP inhibitor, showing statistically significant effects on Alzheimer’s disease biomarkers in cardiovascular patients from the Phase 3 BROADWAY trial.
• The analyses highlight reduced p-tau217 levels, particularly in ApoE4 carriers, hinting at a potential role for obicetrapib in early Alzheimer’s disease prevention alongside its LDL-lowering profile.
• Next, we will examine how obicetrapib’s Alzheimer’s biomarker data, alongside its cardiovascular profile, influences NewAmsterdam Pharma’s broader investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is NewAmsterdam Pharma's Investment Narrative?

To own NewAmsterdam Pharma, you really have to believe obicetrapib can become a meaningful cardiovascular drug and, potentially, open a second chapter in Alzheimer’s prevention. The AAIC 2026 data on p‑tau217 adds scientific depth to that second pillar, but in the near term it probably does not change the central catalysts most shareholders are watching: EMA’s review of obicetrapib in Europe, progress and eventual readout of the PREVAIL outcomes trial, and the company’s ability to fund growing losses while the drug remains pre‑revenue. The Alzheimer’s biomarker package instead nudges the narrative: if the signals hold up, investors may start to think about a longer runway of optionality beyond LDL lowering, even as the core risk profile around trial execution, regulatory decisions and cash burn stays very much intact.

However, one of those risks could matter sooner than some investors might expect. NewAmsterdam Pharma's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Three Simply Wall St Community fair value views span from around US$49.62 to a very large US$1,089.27, underlining how far apart individual expectations sit. When you set those side by side with the company’s ongoing cash burn and execution risk around PREVAIL and regulatory reviews, it becomes clear why many readers choose to compare several perspectives before forming an opinion on NewAmsterdam’s long term potential.

Explore 3 other fair value estimates on NewAmsterdam Pharma - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your NewAmsterdam Pharma research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free NewAmsterdam Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NewAmsterdam Pharma's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.